Abstracts Archive - Page 337 of 1683 - ATC Abstracts

2020 American Transplant Congress
Transmission of Synovial Sarcoma by a Single Multiorgan Donor to Three Solid Organ Transplant Recipients
J. Zhang, J. Lin, Y. Tian
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: To report 3 cases of donor-derived synovial sarcoma (SS) by a single multiorgan donor in China.*Methods: SS was diagnosed by the presence of SS18…
2020 American Transplant Congress
Mycophenolate Mofetil and the Incidence of Skin Cancer in Kidney Transplant Recipients
S. J. Yusuf¹, H. Bheemreddy¹, A. Imtiaz², N. Krishnan³
¹Faculty of Health and Life Sciences, Coventry University, Coventry, United Kingdom, ²Dermatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ³Renal Unit, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
*Purpose: Over the years there has been a shift in the use of anti-metabolites agents from azathioprine to mycophenolate mofetil (MMF) based immunosuppression., due to…
2020 American Transplant Congress
Incidence of Skin Cancer – A Long Term Outcome of Immunosuppression in Renal Transplant Recipients Associated with the Usage of Azathioprine
H. Bheemreddy¹, S. Yusuf¹, N. Krishnan², A. Imtiaz³
¹Health and Life Sciences, Coventry University, Coventry, United Kingdom, ²Renal Unit, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ³Department of Dermatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
*Purpose: The main cause of mortality in Kidney Transplant Recipient’s (KTRs) is malignancy. The cancer incidence is increased by treating with immunosuppressive agents and longer…
2020 American Transplant Congress
Effect of Pre-Transplant Opioid Use on Post Liver Transplant Outcomes
K. Guilbert, H. Underwood, C. J. Simon
Lahey Hospital and Medical Center, Burlington, MA
*Purpose: Impact of pre-liver transplant opioid use on post-liver transplant length of stay and clinical outcomes.*Methods: This single-institution retrospective study included adult patients who received…
2020 American Transplant Congress
Pre-Liver Transplant Coronary Artery Disease Work-Up for Non-High-Risk Patients
C. Walker¹, M. Hook², T. Matyja², J. Buggs³, E. Rogers³, A. Kumar¹, N. Kemmer⁴
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²University of Tampa, Tampa, FL, ³Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁴Transplant Hepatology, Tampa General Hospital, Tampa, FL
*Purpose: Coronary artery disease is a leading cause of mortality following orthotopic liver transplant, yet there is not currently a standardized protocol for pre-liver-transplant coronary…
2020 American Transplant Congress
Incidence and Outcomes of Secondary Cutaneous Malignancies among Renal Transplant Recipients
T. Maw¹, P. Vaidya¹, J. Samaan², S. Ghanshani¹, G. In¹
¹Keck School of Medicine, LA, CA, ²Cedar Sinai Hospital, LA, CA
*Purpose: Solid-organ transplant recipients on immunosuppressive therapy are known to have higher morbidity and mortality from secondary malignancies; however, there are no established guidelines for…
2020 American Transplant Congress
Comparison of Prophylaxis Strategies for CMV Infection in Liver Transplant Recipients
K. Schnelle, A. Leino, M. Chunduru, L. Von Stein, O. Witkowsky
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: The best strategy to prevent cytomegalovirus (CMV) following liver transplantation is not defined for intermediate risk recipients (recipient seropositive (R+) regardless of donor status).…
2020 American Transplant Congress
Early Recurrence Of Hepatocellular Carcinoma Following Transplantation: Risk Score From A Multi-institutional Study Of > 3000 Patients
P. Tabrizian¹, M. Holzner², V. Agopian³, R. Busuttil³, G. Sapisochin⁴, N. Mehta⁵, F. Yao⁵, J. Roberts⁶, S. Florman¹, M. E. Schwartz¹, T. Ivanics⁷, J. Emond⁸, B. Samstein⁹, R. Brown, MD, MPH⁹, M. Najjar¹⁰, W. Chapman¹¹, M. Doyle¹¹, K. Halazun⁹
¹Transplant, Mount Sinai Medical Center, New York, NY, ²Surgery, Georgetown University Hospital, Washington DC, MD, ³Transplant, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Transplant, Univeristy of Toronto, Toronto, ON, Canada, ⁵Transplant, UCSF, San Francisco, CA, ⁶Transplantation, UCSF, San Francisco, CA, ⁷Transplant, University of Toronto, Toronto, ON, Canada, ⁸Transplant, Columbia University Medical Center, New York, NY, ⁹Transplant, Weill Cornell Medical Center, New York, NY, ¹⁰Transplant, Columbia Medical Center, New York, NY, ¹¹Transplant, Washington University School of Medicine, St Louis, MO
*Purpose: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) carries a poor prognosis. We aimed to develop a risk score for early HCC…
2020 American Transplant Congress
Use of 16S Sequencing to Reveal Potential Respiratory Pathogens in Lung Transplant Recipients
C. Eskind¹, M. Shilts¹, H. Boone¹, J. Schmitz², C. Shaver³, S. Das¹, G. Satyanarayana¹
¹Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, ²Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ³Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN
*Purpose: Respiratory infections are common after lung transplant and contribute to mortality and allograft failure. 16S ribosomal RNA (rRNA) gene sequencing could facilitate diagnosis of…
2020 American Transplant Congress
Treatment of Hepatic Encephalopathy in Cirrhotic Patients: Does Rifaximin Prevent Clostridioides Difficile Infection? A Retrospective Analysis
J. D. Goldman, V. Aleksenko, J. L. Davila, N. A. Muhktar, K. Kowdley
Swedish Medical Center, Seattle, WA
*Purpose: Clostridioides difficile infection (CDI) is a major cause of morbidity and mortality and new prevention strategies in high-risk patients are needed. Rifaximin has been…